Foot-and-Mouth Disease Virus Laboratory, Research and Development Centre, Indian Immunologicals Limited, Rakshapuram, Gachibowli Post, Hyderabad 500032, India.
Vaccine. 2011 Feb 24;29(10):1906-12. doi: 10.1016/j.vaccine.2010.12.127. Epub 2011 Jan 13.
Serology is used to predict vaccine induced protection against challenge with a heterologous strain of the same serotype of foot-and-mouth disease virus (FMDV). To evaluate the accuracy of such predictions, we compared the protection afforded to cattle vaccinated with the O(1) Manisa strain of FMDV against challenge with either a homologous (O(1) Manisa) or a heterologous strain (O(1) Campos). Serology by virus neutralization test (VNT) using O(1) Manisa antiserum predicted an acceptable protection against such a challenge. Two experiments were carried out to compare the results for consistency. A total of 78 naïve cattle were vaccinated with different antigen payloads (60-0.94 μg) of O(1) Manisa. They were challenged by intradermolingual inoculation with live FMDV, either O(1) Manisa or O(1) Campos. Unvaccinated naïve control cattle (n=20) were also challenged with either the O(1) Manisa or O(1) Campos viruses and all developed generalized FMD. The protection results for the vaccinated cattle revealed that higher payloads of O(1) Manisa vaccine were needed to protect against heterologous challenge compared to that for homologous challenge. The 50% protective dose (PD(50)) values for the vaccine in experiments 1 and 2 were found to be 28.78 and 9.44 for the homologous challenge and 3.98 and 5.01 for heterologous challenge. Furthermore, protection against O(1) Campos required a higher level of vaccine-induced antibody against this virus compared to the level of O(1) Manisa neutralizing antibody associated with protection against homologous challenge. The 50% protective level of in vitro neutralizing antibody was found to be log(10)1.827 for O(1) Campos and log(10)0.954 for O(1) Manisa based on O(1) Manisa based virus neutralization test.
血清学用于预测疫苗对同源或异源口蹄疫病毒(FMDV)血清型攻击的诱导保护。为了评估此类预测的准确性,我们比较了接种 O(1)Manisa 株 FMDV 的牛对同源(O(1)Manisa)或异源(O(1)Campos)株的保护。使用 O(1)Manisa 抗血清的病毒中和试验(VNT)血清学预测了对这种挑战的可接受保护。进行了两项实验以比较结果的一致性。共有 78 头初免牛接种了不同抗原载量(60-0.94μg)的 O(1)Manisa。它们通过皮内舌接种活 FMDV 进行攻击,要么是 O(1)Manisa,要么是 O(1)Campos。未接种的初免对照牛(n=20)也用 O(1)Manisa 或 O(1)Campos 病毒进行攻击,所有牛都发展为全身性 FMD。接种牛的保护结果表明,与同源攻击相比,需要更高的 O(1)Manisa 疫苗载量来保护免受异源攻击。在实验 1 和 2 中,疫苗的 50%保护剂量(PD(50))值分别为同源攻击的 28.78 和 9.44,以及异源攻击的 3.98 和 5.01。此外,与 O(1)Manisa 中和抗体相关的同源攻击保护相比,对 O(1)Campos 的保护需要更高水平的针对该病毒的疫苗诱导抗体。基于 O(1)Manisa 基于病毒中和试验,发现针对 O(1)Campos 的体外中和抗体的 50%保护水平为 log(10)1.827,针对 O(1)Manisa 的为 log(10)0.954。